期刊文献+

Efficacy and safety of Huaiqihuang granule as adjuvant treatment for primary nephrotic syndrome in children: a meta-analysis and systematic review 被引量:5

原文传递
导出
摘要 Background Huaiqihuang(HQH)granule is a traditional Chinese herbal complex that has been used as an adjuvant treatment in clinics for the primary nephrotic syndrome(PNS)for many years.However,the effectiveness and safety of HQH have not been systematically discussed.This review aimed to evaluate the effectiveness and safety of HQH in paediatric patients with PNS.Methods The following databases were searched from inception to Mar 2019:MEDLINE,Cochrane Library,EMBASE,CNKI,Wanfang Database,the Chinese Scientific Journal Database and the Chinese biomedical literature service system.All the randomized controlled trials(RCTs)eligible for inclusion were included.The primary outcomes were relapse,infection,remission and adverse events.The secondary outcomes included serum immunoglobulin levels(IgA,IgG or IgM),T-lymphocyte subtype(CD3+,CD4+,CD8+,CD4+/CD8+),IL-10,TNF-α,TNF-γ,total cholesterol and time of proteinuria turning negative.Results Fourteen RCTs(885 patients)were identified.Treatment with HQH reduced the chance of relapse[relative risk(RR):0.47;95%CI:0.34,0.66;P<0.001]and infections(RR:0.47;95%Cl:0.35,0.62;P<0.001).No significant difference was found in adverse events.HQH also increased the serum levels of IgA[weighted mean difference(WMD):0.40;95%Cl:0.20,0.60;P<0.001]and IgG(WMD:1.58;95%Cl:1.38-1.78;P<0.001),as well as CD4+[standard mean difference(SMD):0.90;95%Cl:0.12-1.68;P=0.02],CD3+(WMD:4.04;95% CI:3.27-4.82;P<0.001),and the CD4^(+)/CD8^(+)ratio(WMD:0.31;95% CI:0.21-0.41;P<0.001),but decreased the level of CD8+cells(WMD:-3.39;95% CI:-5.73-1.05;P=0.004).No statistically significant difference was found in IgM(WMD:0.05;95% CI:-0.13,0.24;P=0.57).Conclusions HQH could reduce the rate of relapse and the frequency of infection in children with PNS.No apparent adverse effects were found.Moreover,the beneficial influence of HQH may act through immunomodulation.Additional multi-center,large-sample,high-quality studies are needed to confirm the effectiveness and safety of HQH.
出处 《World Journal of Pediatrics》 SCIE CAS CSCD 2021年第3期242-252,共11页 世界儿科杂志(英文版)
基金 supported by the National Natural Foundation of China(81470939 and 81770710) the Natural Science Foundation of Zhejiang Province(LH14H050002,LY15H050001) the Zhejiang Medical and Health Science and Technology Project(2016KYB177).
  • 相关文献

参考文献12

二级参考文献104

共引文献226

同被引文献45

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部